Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 13/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.43 |
| ▸ | CCNK | O75909 | 1/20 | 0.42 |
| ▸ | CCND3 | P30281 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1885643 | 0.83 | BRD4 (0.70) | BRD4ALKPTK2CCNKCCND3 | |
| SCHEMBL1883224 | 0.76 | BRD4 (0.61) | BRD4ALKCCNKCCND3CDK9 | |
| SCHEMBL1885127 | 0.75 | BRD4 (0.60) | BRD4ALKCCNKCCND3CDK9 | |
| SCHEMBL1880046 | 0.72 | ALK (0.54) | BRD4ALKCCNKCCND3CDK9 | |
| SCHEMBL1878922 | 0.72 | ALK (0.49) | BRD4ALKPTK2CCNKCCND3 | |
| SCHEMBL1884694 | 0.71 | BRD4 (0.49) | BRD4ALKPTK2CCNKCCND3 | |
| SCHEMBL25068846 | 0.67 | CDK9 (0.82) | BRD4ALKPTK2CCNKCCND3 | |
| SCHEMBL18757714 | 0.66 | BRD4 (1.00) | BRD4ALK | |
| SCHEMBL1606982 | 0.66 | BRD4 (0.69) | BRD4ALKCCNKCCND3CDK9 | |
| SCHEMBL1607402 | 0.66 | JAK2 (0.52) | BRD4ALKPTK2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080279867-A1 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | claimed |
| US-7947698-B2 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20080279867-A1 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080279867-A1 | Prevent trabsplant rejection; autoimmune diseases | JAK3, JAK1, JAK2 | BRD4 2500/4885ALK 707/4885PTK2 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.